That limitation matters because cross-trial comparisons can be distorted by: different baseline populations different dose-escalation schemes different trial duration different background lifestyle support different endpoint definitions So while it is fair to compare mechanisms and published patterns, it is not rigorous to declare a final winner
Instead, you're building a personal record that helps you and your provider see what is actually happening over time, rather than relying on memories weeks later
The REWIND study evaluated the cardiovascular safety of dulaglutide (1.5 mg) in comparison to placebo ( Exenatide The EXSCEL (Exenatide Study of Cardiovascular Event Lowering) trial evaluated the CV safety of exenatide (2 mg weekly)
doi: 10.1016/j.pharmthera.2022.108270
In a significant deficit, the body prioritizes essential functions over muscle hypertrophy
Researchers call it an immune modulator, meaning that it may help tune the immune system, rather than boosting it